ARONORA INC

Portland, OR · Biotech · Private

AB054, a humanized monoclonal antibody targeting coagulation factor XII (FXII) for anticoagulation during extracorporeal membrane oxygenation and other thrombotic procedures

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · aronorabio.com

Sector: Biotech
Headquarters: Portland, OR
Total capital: $35.1M

Federal grants: $35.1M; 35 awards · 2015–2026; Rank in peer group#116 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 2; 5 pending · first 2020; Rank in peer group#142 of 514

Capital timeline

Latest events

Jun 2026Federal grantHealth and Human S · Phase II · Contact Pathway Inhibitor to Prevent Catheter-Related Thrombosis$1.1M
Jul 2025Federal grantHealth and Human S · Phase II · Contact Pathway Inhibitor to Prevent Vascular Access Failure$1.3M
Jul 2025Federal grantHealth and Human S · Phase II · Contact Pathway Inhibitor to Prevent Catheter-Related Thrombosis$1.1M
Jun 2024Federal grantHealth and Human S · Phase II · Thrombopoietin Targeting in Myeloproliferative Neoplasms$669K
Jun 2024Federal grantHealth and Human S · Phase II · Contact Pathway Inhibitor to Prevent Vascular Access Failure$1.5M
Jun 2024Federal grantHealth and Human S · Phase II · Contact Pathway Inhibitor to Prevent Catheter-Related Thrombosis$494K
Jun 2023Federal grantHealth and Human S · Phase II · Thrombopoietin Targeting in Myeloproliferative Neoplasms$700K

Show 28 earlier federal awards

May 2023Federal grantHealth and Human S · Phase II · Contact Pathway Inhibitor to Prevent Vascular Access Failure$999K
May 2023Federal grantHealth and Human S · Phase II · Antithrombotic Protein C Activator for Hemodialysis$999K
May 2022Federal grantHealth and Human S · Phase II · Factor XII Inhibitor for Surface Initiated Thrombosis$953K
Apr 2022Federal grantHealth and Human S · Phase II · Antithrombotic Protein C Activator for Hemodialysis$999K
Apr 2022Federal grantHealth and Human S · Phase II · Thrombopoietin Targeting in Myeloproliferative Neoplasms$302K
May 2021Federal grantHealth and Human S · Phase II · Factor XII Inhibitor for Surface Initiated Thrombosis$982K
Mar 2021Federal grantHealth and Human S · Phase II · Antithrombotic Protein C Activator for Hemodialysis$998K
Jun 2020Federal grantHealth and Human S · Phase II · Factor XII Inhibitor for Surface Initiated Thrombosis$2.9M
May 2020Federal grantHealth and Human S · Phase II · Factor XII Inhibitor for Surface Initiated Thrombosis$1.0M
May 2020Federal grantHealth and Human S · Phase I · E-WE thrombin for prevention of post-traumatic osteoarthritis$225K
May 2020Federal grantHealth and Human S · Phase II · Antithrombotic Protein C Activator for Hemodialysis$1.5M
Jul 2019Federal grantHealth and Human S · Phase II · Factor XI inhibitor for thrombosis$1.0M
May 2019Federal grantHealth and Human S · Phase II · Antithrombotic Protein C Activator for Hemodialysis$994K
Mar 2019Federal grantHealth and Human S · Phase II · Therapeutic Protein C Activator for Myocardial Ischemia$999K
Jul 2018Federal grantHealth and Human S · Phase II · Factor XI inhibitor for thrombosis$1.0M
Jun 2018Federal grantHealth and Human S · Phase II · HLS- Factor XII Inhibitor for Surface Initiated Thrombosis$963K
Mar 2018Federal grantHealth and Human S · Phase II · Therapeutic Protein C Activator for Myocardial Ischemia$999K
Sep 2017Federal grantHealth and Human S · Phase II · Therapeutic factor XI blockade for sepsis$360K
Jul 2017Federal grantHealth and Human S · Phase II · HLS- Factor XII Inhibitor for Surface Initiated Thrombosis$999K
May 2017Federal grantHealth and Human S · Phase II · Therapeutic Protein C Activator for Myocardial Ischemia$3M
May 2017Federal grantHealth and Human S · Phase II · Therapeutic Protein C Activator for Myocardial Ischemia$998K
Jul 2016Federal grantHealth and Human S · Phase II · HLS- Factor XII Inhibitor for Surface Initiated Thrombosis$300K
Jun 2016Federal grantHealth and Human S · Phase II · Therapeutic Thrombin Analogs$873K
Apr 2016Federal grantHealth and Human S · Phase II · Therapeutic factor XI blockade for sepsis$997K
Jul 2015Federal grantHealth and Human S · Phase II · Therapeutic Protein C Activator for Myocardial Ischemia$5K
Jun 2015Federal grantHealth and Human S · Phase II · Therapeutic Thrombin Analogs$958K
Mar 2015Federal grantHealth and Human S · Phase II · Therapeutic factor XI blockade for sepsis$999K
Feb 2015Federal grantHealth and Human S · Phase II · Therapeutic Protein C Activator for Myocardial Ischemia$946K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#116 · top 23%
Granted patents#142 · top 28%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 2 granted of 7

Nov 5, 2024GrantedTherapeutic Factor Xii AntibodyUSPTOUS 12,134,657
Oct 26, 2023PendingCoordinated Coexpression Of ThrombinUSPTOApplication 18310317
May 19, 2020GrantedNovel Antibodies Against Factor Xi And Uses ThereofUSPTOUS 10,654,941

Show all 7 patent records

Therapeutic Factor Xii AntibodyNov 5, 2024 · US 12,134,657Granted
Coordinated Coexpression Of ThrombinOct 26, 2023 · Application 18310317Pending
Novel Antibodies Against Factor Xi And Uses ThereofMay 19, 2020 · US 10,654,941Granted
Therapeutic Factor Xii AntibodyApplication PCTUS2019063729Pending
Therapeutic Factor Xii AntibodyApplication 62772235Pending
Safe Inhibition Of Tpo ExpressionApplication 62699487Pending
Antibodies Against Factor Xii And Uses ThereofApplication PCTUS2013073690Pending

ELEUTHERIA PHARMACEUTICALS LLCSimilar federal contract value in Biotech · null in contracts
STEMETIX, INC.Similar federal contract value in Biotech · null in contracts
GlycosBio Inc.Similar federal contract value in Biotech · null in contracts
MABVAX THERAPEUTICS HOLDINGS, INC.Similar federal contract value in Biotech · null in contracts
BIOTIME, INC.Similar federal contract value in Biotech · null in contracts
HELIUS MEDICAL TECHNOLOGIES, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.